Q1 FY27 Results: Revenue doubles YoY; 7.8L warrants forfeited

Revenue Growth 20pctPat Growth 25pctNegative Operating CashflowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-0.1%1-day move

₹17.99

prior close

₹18.50

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+2.5+2.5+2.5+2.7-0.1-6.6-2.7-6.6-2.7-2.8-12.0-18.8——

Up moveDown movePending

AI summary

Venmax Drugs Q1 FY27 (quarter ended June 30, 2026): Revenue from operations more than doubled to Rs 247.94 lakh from Rs 121.03 lakh year-on-year. Total revenue stood at Rs 247.96 lakh. Profit after tax rose to Rs 11.66 lakh from Rs 3.74 lakh. EPS at Rs 0.10. Auditor issued an unmodified limited review conclusion. Board also approved forfeiture of 7,80,001 partly paid convertible warrants allotted in March 2025 due to non-payment of balance subscription, retaining about Rs 39 lakh as upfront amount.

Likely market impact

Strong revenue and profit growth signals improving business. Negative operating cash flow remains a watch point despite higher profits.